early esophageal cancer/ precancerous lesion
Conditions
Interventions
treatment group:endoscopic treatment+Celecoxib(200mg bid*7 days preoperative+200mg qd*3 months postoperative)
control group:endoscopic treatment
Sponsors
Department of Gastroenterology, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Pathology confirmed high-grade intraepithelial neoplasia or mucosa cancer of esophageal mucosa; (2) The scope of lesions involving more than 1/2 of the lumen circumference; (3) Endoscopic classification of I, IIa and IIb, IIc type; (4) Lesion invasion less than submucosa without lymph node metastasis identified by endoscopic ultrasonography and chest enhancement CT scan; (5) No obvious heart or lung dysfunction; (6) No blood coagulation disorders.
Exclusion criteria
Exclusion criteria: (1) Inability of resecting en bloc or tumor invasion of muscularis propria or serosa identified by postoperative pathology; (2) Lymph node invasion or local/distant metastasis; (3) History of malignant tumors; (4) Sulphonamide allergy; (5) Severe heart of pulmonary disease; (6) Dysfunction of liver or kidney; (7) Perinatal and nursing mothers; (8) Other NSAIDs using before trail inclusion; (9) Additional postoperative surgery, chemotherapy or radiotherapy; (10) Active peptic ulcer/bleeding; (11) Severe heart failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Esophageal stricture rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| dysphagia scoring;Balloon dilation time; | — |
Countries
China
Contacts
Public ContactHu Bing
Outcome results
None listed